𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor recurrence following liver transplantation for hepatocellular carcinoma: Role of tumor proliferation status

✍ Scribed by Aileen E. Marshall; Simon M. Rushbrook; Sarah L. Vowler; Christopher R. Palmer; R. Justin Davies; Paul Gibbs; Susan E. Davies; Nicholas Coleman; Graeme J. M. Alexander


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
297 KB
Volume
16
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


The selection of patients with hepatocellular carcinoma for liver transplantation is currently based on the size and number of tumors to minimize the risk of recurrence. These criteria measure tumor bulk but may not reflect tumor behavior accurately. A biological marker of tumor behavior could aid with patient selection further. The aims of this study were to determine factors associated with a higher risk of tumor recurrence and to assess the role of tumor proliferation status with respect to recurrence following transplantation. Pathological data on 67 patients who underwent transplantation for hepatocellular carcinoma were reviewed, and tumor proliferation was assessed by minichromosome maintenance protein-2 (MCM-2) and cyclin A expression. A Cox regression analysis of factors related to tumor recurrence and overall survival was carried out. Recurrence-free survival was assessed according to compatibility with selection criteria, vascular invasion, and proliferation status. Tumor size, vascular invasion, and highest MCM-2 expression were associated with tumor recurrence by multivariate analysis (P < 0.02). Recurrence-free survival was significantly better for those patients without vascular invasion, those who were within the Milan, University of California San Francisco (UCSF), or Up-to-Seven selection criteria, and those with lower expression of MCM-2. In conclusion, tumors meeting the Milan, UCSF, or Up-to-Seven selection criteria had a lower rate of recurrence following liver transplantation. Vascular invasion and tumor proliferation status were associated with the risk of recurrence independently of tumor size. Biopsy of larger tumors to assess proliferative activity could identify those at lower risk of recurrence who could also benefit from liver transplantation.


πŸ“œ SIMILAR VOLUMES


Predicting the risk of tumor recurrence
✍ J W Marsh; A Casavilla; S Iwatsuki; I Dvorchik; M Subotin; V Balan; J Rakela; V πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 147 KB πŸ‘ 1 views

be either higher or lower than 1, i.e., having serological mark-to the exposure of interest, constitute a valid and well-accepted comparison group, which has been used in countless ers of infection by hepatitis B and C viruses could be either ''protective'' or ''predisposing'' factors for aplastic a

Analysis of risk factors for tumor recur
✍ Marco Vivarelli; Alessandro Cucchetti; Fabio Piscaglia; Giuliano La Barba; Luigi πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 91 KB

To confirm recent observations about the relationship between immunosuppression and the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT), we retrospectively analyzed 70 consecutive HCC patients who underwent LT and received cyclosporine (CsA) -based immunosuppression. Cs

Total tumor volume predicts risk of recu
✍ Christian Toso; James Trotter; Alice Wei; David L. Bigam; Shimul Shah; Joshua La πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 241 KB

Criteria for the selection of candidates for liver transplantation in the presence of hepatocellular carcinoma (HCC) should accurately predict posttransplant recurrence while not excluding excessive numbers of patients from candidacy. Existing criteria are challenged by the limited accuracy of radio

Tumor surveillance-what can and should b
✍ John P. Roberts πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 71 KB

## Key Points 1. The overall rate of recurrence of hepatocellular carcinoma (HCC) after liver transplantation ranged from 11 to 18% in three of the largest series, with some differences in pre-transplant selection criteria. 2. Patients whose explant pathology is within the currently accepted criter